Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

NCT07455006 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombocytopenia, Immune

Interventions

DRUG: QL0911
DRUG: Placebo

Sponsor

Qilu Pharmaceutical Co., Ltd.